3rd Circ. Won't Rethink Provigil Antitrust Decision
The Third Circuit on Monday declined to reconsider a September ruling vacating a decision certifying purchasers that say Mylan Inc. and Ranbaxy Laboratories Ltd. inked pay-for-delay deals with Provigil maker Cephalon...To view the full article, register now.
Already a subscriber? Click here to view full article